Toggle navigation
Home
About Us
Programs
Investor
Patients
Contact
Toggle navigation
Home
About Us
Programs
Investor
Patients
Contact
Hope
 speaks
WATCH THE VIDEO
The suprachoroidal space
Drugs precisely delivered by suprachoroidal injection with access to the choroid and the retina where the diseases present. 
WATCH ANIMATION
Drugs will be most effective if they can be delivered directly to the part of the eye that requires treatment, such as the choroid and retina”
Henry F. Edelhauser
We 
heard
 you.
Eye diseases such as uveitis, retinal vein occlusion and diabetic macular edema present in the choroid and retina. Through the ingenious efforts of our research and development team, we have developed a unique and elegant way to access to the choroid and retina through the suprachoroidal space to treat these diseases.
PIPELINE
Clinical Program Objectives
Rapid vision gains 
 Sustained better vision improvement 
 Consistent patient response 
 Improved benefits to risk ratio
CLS-TA administered by suprachoroidal injection is currently under investigation in clinical trials.
Not available for clinical use. Not approved by the FDA or other regulatory bodies.
Boundless. Hope.
Let’s get the 
conversation 
going
Questions? We’d love to hear from you.
REQUEST INFORMATION
HOME
ABOUT US
DEVELOPMENT PROGRAMS
INVESTOR RELATIONS
PATIENTS
CAREERS
CONTACT
PRIVACY
Powered by Innovasium